Page 87 - 2022_03-Haematologica-web

Methotrexate neurotoxicity: risk factors & outcome
Chemotherapy. 2003;49(1-2):92-104.
9. Kishi S, Griener J, Cheng C, et al. Homocysteine, pharmacogenetics, and neurotoxicity in children with leukemia. J
Clin Oncol. 2003;21(16):3084-3091.
10. Ramsey LB, Panetta JC, Smith C, et al. Genome-wide study of methotrexate clear- ance replicates SLCO1B1. Blood. 2013;
121(6):898-904.
11. Radtke S, Zolk O, Renner B, et al. Germline
genetic variations in methotrexate candi- date genes are associated with pharmacoki- netics, toxicity, and outcome in childhood acute lymphoblastic leukemia. Blood. 2013; 121(26):5145-5153.
12. Mateos MK, Trahair TN, Mayoh C, et al. Risk factors for symptomatic venous thromboembolism during therapy for childhood acute lymphoblastic leukemia. Thromb Res. 2019;178:132-138.
13. NIH. National Cancer Institute Common Terminology Criteria for Adverse Events v4.0, NCI, NIH, DHHS. NIH publication # 09-7473. 2009.
14. Amos CI, Dennis J, Wang Z, et al. The OncoArray Consortium: a network for understanding the genetic architecture of common cancers. Cancer Epidemiol Biomarkers Prev. 2017;26(1):126-135.
15. Mateos MK, Tulstrup M, Quinn MC, et al. Genome-wide association meta-analysis of single-nucleotide polymorphisms and symptomatic venous thromboembolism during therapy for acute lymphoblastic leukemia and lymphoma in caucasian chil- dren. Cancers. 2020;12(5):1285.
16. Howie B, Marchini J, Stephens M. Genotype imputation with thousands of genomes. G3 (Bethesda). 2011;1(6):457- 470.
17. Holmboe L, Andersen AM, Mørkrid L, Slørdal L, Hall KS. High dose methotrexate chemotherapy: pharmacokinetics, folate and toxicity in osteosarcoma patients. Br J Clin Pharmacol. 2012;73(1):106-114.
18. Pratt DS, Kaplan MM. Evaluation of abnor- mal liver-enzyme results in asymptomatic patients. N Engl J Med. 2000;342(17):1266- 1271.
19.Taylor OA, Brown AL, Brackett J, et al. Disparities in neurotoxicity risk and out- comes among pediatric acute lymphoblas- tic leukemia patients. Clin Cancer Res. 2018;24(20):5012-5017.
20. Csordas K, Hegyi M, Eipel OT, Muller J, Erdelyi DJ, Kovacs GT. Comparison of pharmacokinetics and toxicity after high- dose methotrexate treatments in children with acute lymphoblastic leukemia. Anticancer Drugs. 2013;24(2):189-197.
21. Borsi JD, Moe PJ. A comparative study on the pharmacokinetics of methotrexate in a dose range of 0.5 g to 33.6 g/m2 in children with acute lymphoblastic leukemia. Cancer. 1987;60(1):5-13.
22.Pui C-H, Yang JJ, Hunger SP, et al. Childhood acute lymphoblastic leukemia: progress through collaboration. J Clin Oncol. 2015;33(27):2938-2948.
23. Moricke A, Zimmermann M, Reiter A, et al. Long-term results of five consecutive tri- als in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000. Leukemia. 2009;24(2):265-284.
24. Ochs JJ, Rivera G, Aur R, Hustu H, Berg R, Simone J. Central nervous system morbidi-
ty following an initial isolated central nerv- ous system relapse and its subsequent ther- apy in childhood acute lymphoblastic leukemia. J Clin Oncol. 1985;3(5):622-626.
25. Bonaglia MC, Marelli S, Novara F, et al. Genotype–phenotype relationship in three cases with overlapping 19p13. 12 microdeletions. Eu J Hum Genet. 2010; 18(12):1302-1309.
26. Tabe S, Hikiji H, Ariyoshi W, et al. Lysophosphatidylethanolamine acyltrans- ferase 1/membrane-bound O-acyltrans- ferase 1 regulates morphology and function of P19C6 cell–derived neurons. FASEB J. 2016;30(7):2591-2601.
27. Funato Y, Miki H. Nucleoredoxin, a novel thioredoxin family member involved in cell growth and differentiation. Antioxid Redox Signal. 2007;9(8):1035-1058.
28. Thauerer B, Zur Nedden S, Baier-Bitterlich G. Vital role of protein kinase C-related kinase in the formation and stability of neurites during hypoxia. J Neurochem. 2010;113(2):432-446.
29. Baumgart F, Corral-Escariz M, Pérez-Gil J, Rodríguez-Crespo I. Palmitoylation of R-Ras by human DHHC19, a palmitoyl transferase with a CaaX box. Biochim Biophys Acta. 2010;1798(3):592-604.
30. Winick NJ, Bowman WP, Kamen BA, et al. Unexpected acute neurologic toxicity in the treatment of children with acute lym- phoblastic leukemia. J Natl Cancer Inst. 1992;84(4):252-256.
31. Skärby TC, Anderson H, Heldrup J, Kanerva J, Seidel H, Schmiegelow K. High leucovorin doses during high-dose methotrexate treatment may reduce the cure rate in childhood acute lymphoblastic leukemia. Leukemia. 2006;20(11):1955- 1962.
32. Drachtman RA, Cole PD, Golden CB, et al. Dextromethorphan is effective in the treat- ment of subacute methotrexate neurotoxic- ity. Pediatr Hematol Oncol. 2002;19(5):319- 327.
33. Forster VJ, van Delft FW, Baird SF, Mair S, Skinner R, Halsey C. Drug interactions may be important risk factors for methotrexate neurotoxicity, particularly in pediatric leukemia patients. Cancer Chemother Pharmacol. 2016;78(5):1093-1096.
34. Relling MV, Pui C-H, Sandlund JT, et al. Adverse effect of anticonvulsants on effica- cy of chemotherapy for acute lymphoblas- tic leukaemia. Lancet. 2000;356(9226):285- 290.
35. Diouf B, Crews KR, Lew G, et al. Association of an inherited genetic variant with vincristine-related peripheral neu- ropathy in children with acute lymphoblas- tic leukemia. JAMA. 2015;313(8):815-823.
36. Sutton R, Venn NC, Tolisano J, et al. Clinical significance of minimal residual disease at day 15 and at the end of therapy in child- hood acute lymphoblastic leukaemia. Br J Haematol. 2009;146(3):292-299.
37. Möricke A, Reiter A, Zimmermann M, et al. Risk-adjusted therapy of acute lym- phoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood. 2008;111(9):4477- 4489.
38. Marshall G, Dalla Pozza L, Sutton R, et al. High-risk childhood acute lymphoblastic
leukemia in first remission treated with novel intensive chemotherapy and allo- geneic transplantation. Leukemia. 2013; 27(7):1497-1503.
39. Termuhlen AM, Smith LM, Perkins SL, et al. Disseminated lymphoblastic lymphoma in children and adolescents: results of the COG A5971 trial: a report from the Children's Oncology Group. Br J Haematol. 2013;162(6):792-801.
40.Conter V, Valsecchi MG, Buldini B, et al. Early T-cell precursor acute lymphoblastic leukaemia in children treated in AIEOP centres with AIEOP-BFM protocols: a ret- rospective analysis. Lancet Haematol. 2016;3(2):e80-e86.
41. Nachman JB, Sather HN, Sensel MG, et al. Augmented post-induction therapy for chil- dren with high-risk acute lymphoblastic leukemia and a slow response to initial ther- apy. N Engl J Med. 1998;338(23):1663-1671.
42. Matloub Y, Lindemulder S, Gaynon PS, et al. Intrathecal triple therapy decreases cen- tral nervous system relapse but fails to improve event-free survival when com- pared with intrathecal methotrexate: results of the Children's Cancer Group (CCG) 1952 study for standard-risk acute lymphoblastic leukemia, reported by the Children's Oncology Group. Blood. 2006; 108(4):1165-1173.
43. Seibel NL, Steinherz PG, Sather HN, et al. Early postinduction intensification therapy improves survival for children and adoles- cents with high-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood. 2008;111(5):2548- 2555.
44. Matloub Y, Bostrom BC, Hunger SP, et al. Escalating intravenous methotrexate improves event-free survival in children with standard-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood. 2011;118(2):243- 251.
45.Hunger SP, Loh ML, Whitlock JA, et al. Children's Oncology Group's 2013 blue- print for research: acute lymphoblastic leukemia. Pediatr Blood Cancer. 2013;60(6):957-963.
46.Schultz KR, Bowman WP, Aledo A, et al. Improved early event-free survival with imatinib in Philadelphia chromosome–pos- itive acute lymphoblastic leukemia: a Children's Oncology Group study. J Clin Oncol. 2009;27(31):5175-5181.
47.Larsen EC, Devidas M, Chen S, et al. Dexamethasone and high-dose methotrex- ate improve outcome for children and young adults with high-risk B-acute lym- phoblastic leukemia: a report from Children’s Oncology Group Study AALL0232. J Clin Oncol. 2016;34(20):2380- 2388.
48. Hunger SP, Mullighan CG. Acute lym- phoblastic leukemia in children. N Engl J Med. 2015;373(16):1541-1552.
49. Rodriguez V, Kairalla J, Salzer WL, et al. A pilot study of intensified PEG-asparaginase in high-risk acute lymphoblastic leukemia: Children’s Oncology Group Study AALL08P1. J Pediatr Hematol Oncol. 2016;38(6):409-417.
50. Strichman-Almashanu LZ, Bustin M, Landsman D. Retroposed copies of the HMG genes: a window to genome dynam- ics. Genome Res. 2003;13(5):800-812.
haematologica | 2022; 107(3)
643